ArticleiScience2021
Scalable visible light 3D printing and bioprinting using an organic light-emitting diode microdisplay.
Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Nacre and Nacre-Inspired Materials: Historical Background, Definition, Fabrication Techniques and Gaps.Biomimetics (Basel, Switzerland) · 2026Review
- Fabrication of a visible light photocrosslinkable κ-carrageenan-gelatin hydrogel patch to aid in wound healing applications.Frontiers in bioengineering and biotechnology · 2026Article
- Design considerations for digital light processing bioprinters.Applied physics reviews · 2024Review
- Applications of Light-Based 3D Bioprinting and Photoactive Biomaterials for Tissue Engineering.Materials (Basel, Switzerland) · 2023Review
- Ink Material Selection and Optical Design Considerations in DLP 3D Printing.Applied materials today · 2023Article
- Light-based vat-polymerization bioprinting.Nature reviews. Methods primers · 2023Article
- Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis.Journal for immunotherapy of cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To address current unmet needs in terms of scalability and material biocompatibility for future photocrosslinking-based additive manufacturing technologies, emergent platform designs are in inexorable demand. In particular, a shift from the present use of cell-damaging UV light sources in light-based three-dimensional (3D) bioprinting methods demands new platforms. We adopted an organic light-emitting diode (OLED) microdisplay as a digital visible light modulator to create a 3D printing platform modality that offers scalability and multi-material capability while forgoing the need for UV photocrosslinking. We formulate biocompatible inks that are visible light-crosslinkable with relatively quick photoinitiation rates. We demonstrated successful attachment and rapid growth of primary human dermal fibroblast-adult (HDF-a) cells on biological substrates fabricated using the OLED platform. This platform incites new possibilities by providing a simple-yet-effective means for low-cost, high-throughput, and multi-material 3D fabrication of functional structures made of polymers, ceramic composites, and biomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.